CL2022001464A1 - Polimorfos del compuesto antifúngico de triazol pc945 - Google Patents

Polimorfos del compuesto antifúngico de triazol pc945

Info

Publication number
CL2022001464A1
CL2022001464A1 CL2022001464A CL2022001464A CL2022001464A1 CL 2022001464 A1 CL2022001464 A1 CL 2022001464A1 CL 2022001464 A CL2022001464 A CL 2022001464A CL 2022001464 A CL2022001464 A CL 2022001464A CL 2022001464 A1 CL2022001464 A1 CL 2022001464A1
Authority
CL
Chile
Prior art keywords
polymorphs
antifungal compound
triazole antifungal
compound
triazole
Prior art date
Application number
CL2022001464A
Other languages
English (en)
Spanish (es)
Inventor
Suleiman Osama
Northen Julian
Mykytiuk John
Marshall Jamie
John Wallis Christopher
Steele Gerald
Buttar Suzanne
Original Assignee
Pulmocide Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmocide Ltd filed Critical Pulmocide Ltd
Publication of CL2022001464A1 publication Critical patent/CL2022001464A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2022001464A 2019-12-06 2022-06-02 Polimorfos del compuesto antifúngico de triazol pc945 CL2022001464A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1917867.2A GB201917867D0 (en) 2019-12-06 2019-12-06 Polymorphs

Publications (1)

Publication Number Publication Date
CL2022001464A1 true CL2022001464A1 (es) 2023-03-24

Family

ID=69171938

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001464A CL2022001464A1 (es) 2019-12-06 2022-06-02 Polimorfos del compuesto antifúngico de triazol pc945

Country Status (26)

Country Link
US (2) US12491182B2 (cg-RX-API-DMAC7.html)
EP (2) EP4069690B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023505227A (cg-RX-API-DMAC7.html)
KR (1) KR20220110726A (cg-RX-API-DMAC7.html)
CN (1) CN114746415B (cg-RX-API-DMAC7.html)
AU (1) AU2020397613A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022006259A2 (cg-RX-API-DMAC7.html)
CA (1) CA3155829A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022001464A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022007808A2 (cg-RX-API-DMAC7.html)
DK (1) DK4069690T3 (cg-RX-API-DMAC7.html)
ES (1) ES3000984T3 (cg-RX-API-DMAC7.html)
FI (1) FI4069690T3 (cg-RX-API-DMAC7.html)
GB (1) GB201917867D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20250042T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069799T2 (cg-RX-API-DMAC7.html)
IL (1) IL293401B1 (cg-RX-API-DMAC7.html)
LT (1) LT4069690T (cg-RX-API-DMAC7.html)
MX (1) MX2022006654A (cg-RX-API-DMAC7.html)
PL (1) PL4069690T3 (cg-RX-API-DMAC7.html)
PT (1) PT4069690T (cg-RX-API-DMAC7.html)
RS (1) RS66401B1 (cg-RX-API-DMAC7.html)
SA (1) SA522432879B1 (cg-RX-API-DMAC7.html)
SI (1) SI4069690T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400514T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021111142A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016087880A1 (en) 2014-12-05 2016-06-09 Pulmocide Limited Antimycotic compound
CN117510488B (zh) * 2022-07-28 2025-12-05 博瑞制药(苏州)有限公司 一种硫酸艾沙康唑的制备方法
CN117330660A (zh) * 2023-09-14 2024-01-02 广州医科大学附属第一医院(广州呼吸中心) Uplc-ms/ms联用检测艾沙康唑的方法及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1292472C (en) 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles
AU2811689A (en) 1987-11-20 1989-06-14 Schering Corporation Tri-and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
US5039676A (en) 1990-05-11 1991-08-13 Schering Corporation Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
DK0736030T3 (da) 1993-12-21 2001-10-29 Schering Corp Fungicide tetrahydrofuraner
US5714490A (en) 1993-12-21 1998-02-03 Schering Corporation Tetrahydrofuran antifungals
US5486625A (en) 1994-07-08 1996-01-23 Schering Corporation Process for the preparation of chiral intermediates useful for the synthesis of antifungal agents
ES2199291T3 (es) 1995-06-02 2004-02-16 Schering Corporation Antifungicos de tetrahidrofurano.
EP0957101A1 (en) 1998-05-14 1999-11-17 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals
PL212985B1 (pl) 2001-04-03 2012-12-31 Schering Corp Ciekla zawiesina zawierajaca przeciwgrzybiczo skuteczna ilosc posakonazolu oraz zastosowanie zmikronizowanych czastek posakonazolu
EP2141159A1 (en) * 2008-07-03 2010-01-06 Sandoz AG A Crystalline form of posaconazole
WO2013036866A1 (en) 2011-09-07 2013-03-14 The Johns Hopkins University Itraconazole analogs and use thereof
WO2016087880A1 (en) * 2014-12-05 2016-06-09 Pulmocide Limited Antimycotic compound

Also Published As

Publication number Publication date
KR20220110726A (ko) 2022-08-09
CN114746415B (zh) 2025-04-11
PT4069690T (pt) 2024-12-13
LT4069690T (lt) 2025-01-10
CN114746415A (zh) 2022-07-12
JP2023505227A (ja) 2023-02-08
EP4509179A2 (en) 2025-02-19
HUE069799T2 (hu) 2025-04-28
IL293401B1 (en) 2026-08-01
MX2022006654A (es) 2022-09-07
US20260060980A1 (en) 2026-03-05
CO2022007808A2 (es) 2022-06-30
SMT202400514T1 (it) 2025-01-14
ES3000984T3 (es) 2025-03-04
SA522432879B1 (ar) 2025-01-26
EP4069690A1 (en) 2022-10-12
HRP20250042T1 (hr) 2025-03-14
US12491182B2 (en) 2025-12-09
WO2021111142A1 (en) 2021-06-10
DK4069690T3 (da) 2025-01-20
PL4069690T3 (pl) 2025-03-10
BR112022006259A2 (pt) 2022-06-21
FI4069690T3 (fi) 2025-01-21
SI4069690T1 (sl) 2025-03-31
IL293401A (en) 2022-07-01
EP4069690B1 (en) 2024-11-13
AU2020397613A1 (en) 2022-06-02
CA3155829A1 (en) 2021-06-10
US20230028714A1 (en) 2023-01-26
GB201917867D0 (en) 2020-01-22
EP4509179A3 (en) 2025-02-26
RS66401B1 (sr) 2025-02-28

Similar Documents

Publication Publication Date Title
CO2022007808A2 (es) Polimorfos del compuesto antifúngico de triazol pc945
MX2020005323A (es) Triazol azinas de acido ciclohexilo como antagonistas de acido lisofosfatidico (lpa).
CL2020001547A1 (es) Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa.
MX2020005818A (es) Triazol azoles de acido ciclohexilo como antagonistas de acido lisofosfatidico (lpa).
ECSP20075270A (es) Compuestos
MX381205B (es) Acidos de carbamoiloximetil triazol ciclohexilo como antagonistas de acido lisofosfatidico (lpa).
SI4055021T1 (sl) Heterociklične spojine, ki inhibirajo rip1
IL320185A (en) Heterocyclic compound
CL2021000454A1 (es) Método para preparar 2-[(3r)-3--metilmofolin--4-il]-4-(1-metil-1h-pirazol-5-il)-8-(1h-pirazol-5-il)-1,7-naftiridina
GB202212641D0 (en) Novel compounds
EP4037687A4 (en) BENZOXAZINONE COMPOUNDS AS DUAL KLK5/7 INHIBITORS
GB202202921D0 (en) Novel compounds
GB202302686D0 (en) Novel compounds
GB202300833D0 (en) Novel compounds
GB202217575D0 (en) Novel compounds
MX2024011757A (es) Proceso para preparar compuestos de acido carbamoiloximetil triazol ciclohexilico
GB202216323D0 (en) Novel compounds
GB202206054D0 (en) Novel Compounds
ZA202408061B (en) Benzotriazole compound
GB202304448D0 (en) Novel compounds
GB202302534D0 (en) Novel compounds
GB202301448D0 (en) Novel compounds
GB202218818D0 (en) Novel compounds
GB202217865D0 (en) Novel compounds
GB202217862D0 (en) Novel compounds